• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Ital J Pediatr . Sensitivity of three commercial tests for SARS-CoV-2 serology in children: an Italian multicentre prospective study

tetano

Editor, Senior Moderator
Ital J Pediatr


. 2022 Dec 2;48(1):192.
doi: 10.1186/s13052-022-01381-9.
Sensitivity of three commercial tests for SARS-CoV-2 serology in children: an Italian multicentre prospective study


Elisabetta Venturini[SUP] 1 [/SUP], Sabrina Giometto[SUP] 2 [/SUP], Agnese Tamborino[SUP] 1 [/SUP], Laura Becciolini[SUP] 3 [/SUP], Samantha Bosis[SUP] 4 [/SUP], Giovanni Corsello[SUP] 5 [/SUP], Paolo Del Barba[SUP] 6 [/SUP], Silvia Garazzino[SUP] 7 [/SUP], Andrea Lo Vecchio[SUP] 8 [/SUP], Alessandra Pugi[SUP] 9 [/SUP], Sara Signa[SUP] 10 [/SUP], Giacomo Stera[SUP] 11 [/SUP], Sandra Trapani[SUP] 12 [/SUP], Guido Castelli Gattinara[SUP] 13 [/SUP], Ersilia Lucenteforte[SUP] 2 [/SUP], Luisa Galli[SUP] 14 15 [/SUP]



Affiliations
Free article

Abstract

Background: US Food and Drug Administration has issued Emergency Use Authorizations for hundreds of serological assays to support Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) diagnosis. The aim of this study is to evaluate, for the first time in children, the performance of three widely utilized SARS-CoV-2 serology commercial assays, Diesse Diagnostics (IgG, IgA, IgM) and Roche Diagnostics, both Roche Nucleocapsid (N) IgG and Roche Spike (S) IgG assays.
Methods: Sensitivity and 95% confidence intervals (CIs) were estimated for each of the three different serological tests and mixed and direct comparison were performed. Univariate and multivariate Poisson regression models were fitted to calculate incidence rate ratios and 95% CIs as estimate of the effects of age, gender, time on the serology title. A p-value < 0.05 indicated statistical significance.
Results: Overall, 149 children were enrolled in the study. A low sensitivity was found for Diesse IgA, IgM and IgG. Compare to Diesse, Roche S had a higher sensitivity at 15-28 days from infection (0.94, 95%CI: 0.73-1.0) and Roche N at 28-84 days (0.78, 95%CI: 0.58-0.91). When a direct comparison of IgG tests sensitivity was feasible for patients with pairwise information, Roche S and Roche N showed a statistically significant higher sensitivity compared to Diesse in all the study periods, whereas there was no difference between the two Roche tests.
Conclusion: Roche S and Roche N serology tests seem to better perform in children. Large prospective studies are needed to better define the characteristics of those tests.

Keywords: COVID-19; Children; Electrochemiluminescent immunoassay (ECLIA); Enzyme-linked immunosorbent assay (ELISA); SARS-CoV-2.
 
Back
Top Bottom